



08-16-04

IFW AF
1644

Corres. and Mail

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person shall be required to respond to a collection of information unless it displays a valid OMB control number.

BOX AF

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

13

Filing Date

09/349,915

July 8, 1999

First Named Inventor

June et al.

Art Unit

1644

Examiner Name

Phillip Gambel

Attorney Docket Number

36119.125US10

ENCLOSURES (Check all that apply)



Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)

Response to Missing Parts/
Incomplete ApplicationResponse to Missing Parts
under 37 CFR 1.52 or 1.53

Drawing(s)



Licensing-related Papers



Petition

Petition to Convert to a
Provisional ApplicationPower of Attorney, Revocation
Change of Correspondence Address

Terminal Disclaimer



Request for Refund



CD, Number of CD(s) _____

After Allowance communication
to Technology Center (TC)Appeal Communication to Board
of Appeals and InterferencesAppeal Communication to TC
(Appeal Notice, Brief, Reply Brief)

Proprietary Information



Status Letter

Other Enclosure(s) (please
Identify below):

Remarks

- Second Supplemental Response Pursuant to 37 C.F.R.
Sec. 1.116 (12 Pages)
- Return Postcard

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
or
Individual name

Colleen Superko, Reg. No. 39,850

Signature

Date

August 13, 2004

EXPRESS MAIL LABEL NO. EVJ0820349805
DATE OF DEPOSIT 8/13/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	09/349,915	Art Unit:	1644
Applicant:	June <i>et al.</i>	Examiner:	Phillip Gambel
Date Filed:	July 8, 1999	Conf. No.	7335
Docket No.	36119.125US10	Cust. No.	23483
Title:	Methods for Selectively Stimulating Proliferation of T Cells		

CERTIFICATION UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EV 50820349805
Express Mail No.

8/13/04
Date of Deposit

Sharon R. Matthews
Sharon R. Matthews

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL RESPONSE PURSUANT TO 37 C.F.R. § 1.116

Sir:

In further response to the Final Office Action dated *April 13, 2004* and Applicants' Amendment and Response dated May 3, 2004, and Supplemental Amendment dated July 22, 2004, Applicants respectfully request that the above-referenced application be amended as follows:

Amendments to the Claims are reflected in the listing of claims which begins on *page 2* of this paper.

Remarks begin on *page 5* of this paper.

An **Appendix** documenting the availability of the 9.3 antibody is attached following *page 6* of this paper.